Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: * written informed consent obtained before any trial related procedures are performed * age ≥ 18 years * hospitalized patients with pcr confirmed sars-cov-2 infection and symptom onset ≤ 10 days before randomization * patients with respiratory covid-19 symptoms * randomization ≤ 48h from admission * peripheral capillary oxygen saturation (spo2) ≥ 90% on room air or supplemental oxygen at screening * patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges)

inclusion criteria: * written informed consent obtained before any trial related procedures are performed * age ≥ 18 years * hospitalized patients with pcr confirmed sars-cov-2 infection and symptom onset ≤ 10 days before randomization * patients with respiratory covid-19 symptoms * randomization ≤ 48h from admission * peripheral capillary oxygen saturation (spo2) ≥ 90% on room air or supplemental oxygen at screening * patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges)

March 13, 2021, 12:31 a.m. usa

inclusion criteria: - written informed consent obtained before any trial related procedures are performed - age ≥ 18 years - hospitalized patients with pcr confirmed sars-cov-2 infection and symptom onset ≤ 10 days before randomization - patients with respiratory covid-19 symptoms - randomization ≤ 48h from admission - peripheral capillary oxygen saturation (spo2) ≥ 90% on room air or supplemental oxygen at screening - patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges)

inclusion criteria: - written informed consent obtained before any trial related procedures are performed - age ≥ 18 years - hospitalized patients with pcr confirmed sars-cov-2 infection and symptom onset ≤ 10 days before randomization - patients with respiratory covid-19 symptoms - randomization ≤ 48h from admission - peripheral capillary oxygen saturation (spo2) ≥ 90% on room air or supplemental oxygen at screening - patient agrees to refrain from taking other carragelose products (e.g. throat spray, lozenges)